Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abgenix, CuraGen develop up to 250 antibodies

Executive Summary

Under terms of a five-year collaboration, Abgenix and CuraGen will develop and test up to 250 antibody drug candidates. The deal is an expansion of the partners' 1999 agreement to develop up to 120 compounds.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Co-Promotion
    • Includes Contract
    • Product or Technology Swap

Related Companies

Advertisement
UsernamePublicRestriction

Register